Recent Improvements in the Clinical Treatment of Coagulation Factor Inhibitors

ABSTRACT

The mainstay of therapy in patients with congenital hemophilia is factor replacement. However, the development of inhibitors in these patients is a major complication that represents an important challenge in hemophilia care. Development of inhibitors complicates the clinical course of severe hemophilia in up to 30% of patients with hemophilia A and up to 5% of patients with hemophilia B. Although the main short-term objective of the treatment of alloantibodies against factors VIIII and IX is to control the bleeding diathesis, the eradication of the inhibitor is the leading long-term goal. The management of severe bleeding episodes and the definitive eradication of the autoantibody are also the two main options of the clinical management of patients with acquired hemophilia, a rare but life-threatening hemorrhagic condition. The most recent options available for treating patients with acquired hemophilia and congenital hemophilia with inhibitors are addressed in this review.

KEYWORDS

Inhibitors - hemophilia - bleeding - immune tolerance - therapy

REFERENCES

• 1 Haya S, Moret A, Cid A R et al.. Inhibitors in haemophilia A: current management and open issues.  Haemophilia. 2007;  13(Suppl 5) 52-60
• 2 Lusher J M. Inhibitor antibodies to factor VIII and factor IX: management.  Semin Thromb Hemost. 2000;  26(2) 179-188
• 3 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A.  Clin Chim Acta. 2008;  395(1-2) 14-18
• 4 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review.  Haemophilia. 2003;  9(4) 418-435
• 5 Scandella D H. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients.  Semin Thromb Hemost. 2000;  26(2) 137-142
• 6 Moreau A, Lacroix-Desmazes S, Stieltjes N et al.. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG.  Blood. 2000;  95(11) 3435-3441
• 7 Spiegel Jr P C, Jacquemin M, Saint-Remy J M, Stoddard B L, Pratt K P. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.  Blood. 2001;  98(1) 13-19
• 8 Lee C A, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.  Semin Thromb Hemost. 2006;  32(Suppl 2) 10-14
• 9 Gouw S C, van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.  Semin Thromb Hemost. 2009;  35(8) 723-734
• 10 Gill J C. The role of genetics in inhibitor formation.  Thromb Haemost. 1999;  82(2) 500-504
• 11 Astermark J, Berntorp E, White G C, Kroner B L. MIBS Study Group . The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients.  Haemophilia. 2001;  7(3) 267-272
• 12 Aledort L M, Dimichele D M. Inhibitors occur more frequently in African-American and Latino haemophiliacs.  Haemophilia. 1998;  4(1) 68
• 13 Hay C R, Ollier W, Pepper L UKHCDO Inhibitor Working Party et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A.  Thromb Haemost. 1997;  77(2) 234-237
• 14 Oldenburg J, Schröder J, Brackmann H H, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development.  Semin Hematol. 2004;  41(Suppl 1) 82-88
• 15 Santagostino E, Mancuso M E, Rocino A et al.. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study.  Br J Haematol. 2005;  130(3) 422-427
• 16 Gouw S C, van der Bom J G, Auerswald G, Ettinghausen C E, Tedgård U, van den Berg H M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.  Blood. 2007;  109(11) 4693-4697
• 17 Goudemand J, Rothschild C, Demiguel V et al.. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.  Blood. 2006;  107(1) 46-51
• 18 Chalmers E A, Brown S A, Keeling D Paediatric Working Party of UKHCDO et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.  Haemophilia. 2007;  13(2) 149-155
• 19 Berntorp E, Shapiro A, Astermark J et al.. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.  Haemophilia. 2006;  12(Suppl 6) 1-7
• 20 Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia.  Semin Thromb Hemost. 2000;  26(2) 205-208
• 21 Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis.  Haemophilia. 1998;  4(4) 574-576
• 22 Astermark J. Treatment of the bleeding inhibitor patient.  Semin Thromb Hemost. 2003;  29(1) 77-86
• 23 von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.  Haemophilia. 2005;  11(Suppl 1) 18-23
• 24 Parameswaran R, Shapiro A D, Gill J C, Kessler C M. HTRS Registry Investigators . Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.  Haemophilia. 2005;  11(2) 100-106
• 25 Santagostino E, Mancuso M E, Rocino A, Mancuso G, Scaraggi F, Mannucci P M. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.  J Thromb Haemost. 2006;  4(2) 367-371
• 26 Young G, Shafer F E, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.  Haemophilia. 2008;  14(2) 287-294
• 27 Franchini M, Sassi M, Dell'Anna P et al.. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors.  Semin Thromb Hemost. 2009;  35(1) 76-80
• 28 Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.  Haemophilia. 2008;  14(Suppl 3) 196-201
• 29 Franchini M, Manzato F, Salvagno G L, Montagnana M, Zaffanello M, Lippi G. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant FVIIa.  Semin Thromb Hemost. 2009;  35(8) 814-819
• 30 DiMichele D M, Hoots W K, Pipe S W, Rivard G E, Santagostino E. International workshop on immune tolerance induction: consensus recommendations.  Haemophilia. 2007;  (13 Suppl 1) 1-22
• 31 Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia—principal results from the International Registry. Report of the factor VIII and IX Subcommittee.  Thromb Haemost. 1994;  72(1) 155-158
• 32 DiMichele D M, Kroner B L. North American Immune Tolerance Study Group . The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.  Thromb Haemost. 2002;  87(1) 52-57
• 33 Lenk H. ITT Study Group . The German Registry of immune tolerance treatment in hemophilia—1999 update.  Haematologica. 2000;  85(10 Suppl) 45-47
• 34 Kroner B L. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry.  Vox Sang. 1999;  77(Suppl 1) 33-37
• 35 Haya S, Quintana M, Aznar J et al.. Registro español de inmunotolerancia en hemofilicos con inhibidores. Actualización a 2005.  Haematologica. 2006;  91(Spanish ed., Suppl 4) 1-5
• 36 DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.  Haemophilia. 2009;  15(1) 320-328
• 37 Dimichele D M, Hay C R. The International Immune Tolerance Study: a multicenter prospective randomized trial in progress.  J Thromb Haemost. 2006;  4(10) 2271-2273
• 38 Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.  Haemophilia. 2007;  13(Suppl 5) 73-77
• 39 Hay C R, Brown S, Collins P W, Keeling D M, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors' Organisation.  Br J Haematol. 2006;  133(6) 591-605
• 40 Key N S. Inhibitors in congenital coagulation disorders.  Br J Haematol. 2004;  127(4) 379-391
• 41 Biss T T, Velangi M R, Hanley J P. Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature.  Haemophilia. 2006;  12(3) 280-284
• 42 Fox R A, Neufeld E J, Bennett C M. Rituximab for adolescents with haemophilia and high titre inhibitors.  Haemophilia. 2006;  12(3) 218-222
• 43 Carcao M, St Louis J, Poon M C Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.  Haemophilia. 2006;  12(1) 7-18
• 44 Franchini M, Mengoli C, Lippi G et al.. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis.  Haemophilia. 2008;  14(5) 903-912
• 45 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.  Br J Haematol. 2003;  121(1) 21-35
• 46 Cohen A J, Kessler C M. Acquired inhibitors.  Baillieres Clin Haematol. 1996;  9(2) 331-354
• 47 Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review.  Am J Hematol. 2005;  80(1) 55-63
• 48 Hay C RM, Baglin T P, Collins P W, Hill F GH, Keeling D M. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).  Br J Haematol. 2000;  111(1) 78-90
• 49 Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A.  Br J Haematol. 2004;  124(1) 86-90
• 50 Collins P W, Hirsch S, Baglin T P UK Haemophilia Centre Doctors' Organisation et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.  Blood. 2007;  109(5) 1870-1877
• 51 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII.  Thromb Haemost. 1981;  45(3) 200-203
• 52 Bossi P, Cabane J, Ninet J et al.. Acquired hemophilia due to factor VIII inhibitors in 34 patients.  Am J Med. 1998;  105(5) 400-408
• 53 Yee T T, Pasi K J, Lilley P A, Lee C A. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964–97.  Br J Haematol. 1999;  104(4) 909-914
• 54 Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey.  Am J Hematol. 1998;  59(1) 1-4
• 55 Franchini M. Postpartum acquired factor VIII inhibitors.  Am J Hematol. 2006;  81(10) 768-773
• 56 Trotta F, Bajocchi G, La Corte R, Moratelli S, Sun L Y. Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus.  Rheumatology (Oxford). 1999;  38(10) 1007-1009
• 57 Soriano R M, Matthews J M, Guerado-Parra E. Acquired haemophilia and rheumatoid arthritis.  Br J Rheumatol. 1987;  26(5) 381-383
• 58 Meiklejohn D J, Watson H G. Acquired haemophilia in association with organ-specific autoimmune disease.  Haemophilia. 2001;  7(5) 523-525
• 59 Hauser I, Lechner K. Solid tumors and factor VIII antibodies.  Thromb Haemost. 1999;  82(3) 1005-1007
• 60 Sallah S, Wan J Y. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients.  Cancer. 2001;  91(6) 1067-1074
• 61 Franchini M, Targher G, Manzato F, Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review.  Crit Rev Oncol Hematol. 2008;  66(3) 194-199
• 62 Sallah S, Nguyen N P, Abdallah J M, Hanrahan L R. Acquired hemophilia in patients with hematologic malignancies.  Arch Pathol Lab Med. 2000;  124(5) 730-734
• 63 Dentale N, Fulgaro C, Guerra L, Fasulo G, Mazzetti M, Fabbri C. Acquisition of factor VIII inhibitor after acute hepatitis C virus infection.  Blood. 1997;  90(8) 3233-3234
• 64 Sallah S, Wan J Y. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.  Thromb Haemost. 2001;  86(4) 1119-1121
• 65 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A.  Clin Chim Acta. 2008;  395(1-2) 14-18
• 66 Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia centre.  Semin Thromb Hemost. 2009;  35(8) 760-768
• 67 Scandella D, Gilbert G E, Shima M et al.. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.  Blood. 1995;  86(5) 1811-1819
• 68 Franchini M, Lippi G. Acquired factor VIII inhibitors.  Blood. 2008;  112(2) 250-255
• 69 Kessler C M. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future.  Haematologica. 2000;  85(10, Suppl) 57-61, discussion 61–63
• 70 Collins P W. Treatment of acquired hemophilia A.  J Thromb Haemost. 2007;  5(5) 893-900
• 71 Mudad R, Kane W H. DDAVP in acquired hemophilia A: case report and review of the literature.  Am J Hematol. 1993;  43(4) 295-299
• 72 Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity.  Haemophilia. 2004;  10(2) 169-173
• 73 Hay C R, Negrier C, Ludlam C A. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study.  Thromb Haemost. 1997;  78 1463-1467
• 74 Sumner M J, Geldziler B D, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.  Haemophilia. 2007;  13(5) 451-461
• 75 Schwartz R S, Gabriel D A, Aledort L M, Green D, Kessler C M. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin.  Blood. 1995;  86(2) 797-804
• 76 Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide.  Blood. 1971;  37(4) 381-387
• 77 Spero J A, Lewis J H, Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors.  Br J Haematol. 1981;  48(4) 635-642
• 78 Shaffer L G, Phillips M D. Successful treatment of acquired hemophilia with oral immunosuppressive therapy.  Ann Intern Med. 1997;  127(3) 206-209
• 79 Lian E C, Larcada A F, Chiu A Y. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor.  Ann Intern Med. 1989;  110(10) 774-778
• 80 Green D, Rademaker A W, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies.  Thromb Haemost. 1993;  70(5) 753-757
• 81 Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies.  Haematologica. 2000;  85(8) 895-896
• 82 Lottenberg R, Kentro T B, Kitchens C S. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy.  Arch Intern Med. 1987;  147(6) 1077-1081
• 83 Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.  Blood. 2004;  103(12) 4424-4428
• 84 Wiestner A, Cho H J, Asch A S et al.. Rituximab in the treatment of acquired factor VIII inhibitors.  Blood. 2002;  100(9) 3426-3428
• 85 Onitilo A A, Skorupa A, Lal A et al.. Rituximab in the treatment of acquired factor VIII inhibitors.  Thromb Haemost. 2006;  96(1) 84-87
• 86 Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review.  Crit Rev Oncol Hematol. 2007;  63(1) 47-52
• 87 Nemes L, Pitlik E. Ten years experience with immune tolerance induction therapy in acquired hemophilia.  Haematologica. 2003;  88(Suppl 12) 106-110
• 88 Zeitler H, Ulrich-Merzenich G, Hess L et al.. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.  Blood. 2005;  105(6) 2287-2293